

## Occurrence and Potential Diagnostic Applications of Serological Cross-Reactivities between *Brucella* and Other Alpha-Proteobacteria

M. Victoria Delpino, Carlos A. Fossati, and Pablo C. Baldi\*

Instituto de Estudios de la Inmunidad Humoral, Facultad de Farmacia y Bioquímica,  
Universidad de Buenos Aires, Buenos Aires, Argentina

Received 27 April 2004/Returned for modification 14 June 2004/Accepted 28 June 2004

*Agrobacterium*, *Sinorhizobium*, and *Ochrobactrum* are genera closely related to *Brucella* but, in contrast to the latter, are not pathogenic for humans and animals. We studied by an indirect enzyme-linked immunosorbent assay (ELISA) the reactivities of brucellosis sera against cytosolic (CYT) and membrane (MA) antigens from these nonpathogenic bacteria, and we evaluated the potential usefulness of these cross-reactions for the diagnosis of brucellosis in humans, sheep, cows, and dogs. Canine infection by *Brucella canis* was detected with high specificity by CYT antigen-based ELISAs (96% for *Agrobacterium*, 96% for *Sinorhizobium*, and 91% for *Ochrobactrum*), while sensitivity was variable (58% for *Agrobacterium*, 88% for *Sinorhizobium*, and 84% for *Ochrobactrum*). In addition, it was possible to diagnose canine disease shortly after exposure to the pathogen (15 days). Similar results for canine brucellosis were obtained with MA antigens. In contrast, normal sera from humans, sheep, and cattle reacted strongly with all the antigens (CYT and MA antigens from the three bacteria), producing high cutoff values and, consequently, low sensitivities. While for some host species the reactivity patterns of normal sera by Western blotting were similar to those produced with sera from infected individuals, the reactivity pattern of bovine sera against *Sinorhizobium meliloti* antigens exhibited some differential bands for the two groups of sera. These results show that crude fractions from nonpathogenic alpha-proteobacteria can be used to diagnose canine brucellosis but may need to be further separated into simpler fractions to have diagnostic usefulness in ovine, bovine, or human infection. By reducing the biosafety requirements, the use of antigens derived from these nonpathogenic bacteria would simplify the production of diagnostic kits for brucellosis, especially in settings where biosafety level-3 facilities are scarce or absent.

Members of the genus *Brucella* cause brucellosis, an infectious disease affecting livestock and humans. *Brucella* spp. belong to the alpha-2 subgroup of *Proteobacteria*, which also includes *Agrobacterium*, *Rhizobium*, and *Ochrobactrum*, among other genera (13). There are several lines of evidence about the close genetic and antigenic relationship between *Brucella* and other alpha-proteobacteria. Analysis of the complete set of predicted *Brucella suis* proteins has revealed that it is very similar to that of species in the *Rhizobium/Agrobacterium* group. A total of 1,902 *B. suis* open reading frames are conserved in *Mesorhizobium loti*, *Sinorhizobium meliloti*, and *Agrobacterium tumefaciens*, and 2,408 *B. suis* open reading frames are conserved in at least one of these three genomes (14). Similar relationships were found when the genome of *Brucella melitensis* was analyzed (8).

While the natural hosts for *Brucella* species are animals and humans, some related alpha-proteobacteria usually live in the soil (*Ochrobactrum* spp.), establish symbiotic relationships with plants (*Rhizobium* spp.), or are phytopathogens (*Agrobacterium* spp.). *Rhizobium*, *Bradyrhizobium*, and *Sinorhizobium* spp. and related bacteria induce the formation of nitrogen-fixing nodules on their leguminous hosts (10). In contrast, *A. tumefaciens*

attacks wounded plant tissues and induces neoplastic growths called crown galls (15).

In contrast to the high pathogenic potential of most *Brucella* species, many related alpha-proteobacteria either are not pathogenic for immunocompetent individuals or show only limited pathogenicity. Human infections by *A. tumefaciens* have been reported almost exclusively in immunocompromised patients with indwelling catheters or prosthetic cardiac valves (1, 2). Similarly, infections by *Ochrobactrum anthropi* have occurred mostly in patients with debilitating underlying diseases (acute leukemia, human immunodeficiency virus infection) or those under chemotherapy (1, 12). Thus, the risk of *Agrobacterium* or *Ochrobactrum* infection for immunocompetent individuals appears extremely low. In addition, there are no reports of human disease caused by *Rhizobium* or other nodule-forming bacteria (although *A. tumefaciens* may appear under the name *Rhizobium radiobacter* in some papers).

In spite of the homologies revealed by computational analyses, few studies have investigated the serological cross-reactivity between proteins from *Brucella* and those from related alpha-proteobacteria. A notable exception is the study by Velasco et al., who found extensive cross-reactivity between cytosolic proteins from *B. melitensis* and those from *O. anthropi* (16). Some cross-reactions were also found at the level of outer membrane proteins and lipopolysaccharide (LPS) (core and lipid A). No similar study has been performed with antigens from other alpha-proteobacteria. Thus, the first goal of the present study was to study serological cross-reactivities be-

\* Corresponding author. Mailing address: Instituto de Estudios de la Inmunidad Humoral (IDEHU), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956 4to. piso, 1113 Buenos Aires, Argentina. Phone: 54-11-4964-8259. Fax: 54-11-4964-0024. E mail: pabloal@ffyb.uba.ar.

tween antigens from *Brucella* and those from *A. tumefaciens* and *S. meliloti*.

While serological cross-reactivities between common pathogens can cause difficulties in the differential diagnosis of infections by such pathogens, cross-reactivity can have diagnostic usefulness if one of the cross-reacting species is not pathogenic and is unlikely to enter the host. Under these conditions, cross-reacting antigens could be obtained from the nonpathogenic species and used for the diagnosis of infections caused by the pathogenic agent. The production of antigens for the serological diagnosis of brucellosis involves the handling of live brucellae, which are dangerous pathogens. Large-scale culture of *Brucella* for antigen production requires biosafety level-3 (BSL-3) facilities (6), which are seldom available in the developing countries where brucellosis is more prevalent. In contrast, antigens from nonpathogenic alpha-proteobacteria can be obtained without the need for special biosafety measures. Therefore, the second goal of this study was to test whether crude cytosolic (CYT) and membrane (MA) fractions from innocuous alpha-proteobacteria can be used to diagnose human and animal brucellosis. To the best of our knowledge, this is the first study in which antigens from nonpathogenic bacteria have been used to diagnose an infectious disease caused by bacteria from a different but related genus.

#### MATERIALS AND METHODS

**Serum samples.** All the human and animal sera included in the study had been used in previous investigations and were positive by enzyme-linked immunosorbent assay (ELISA) against LPS-free CP of *Brucella* and against *Brucella* LPS. The preparation of the CP antigen and ELISAs used for testing anti-CP and anti-LPS antibodies are described elsewhere (3, 17).

**Ovine sera.** Sera from 42 *Brucella*-infected sheep (kindly provided by I. Moriñón, Pamplona, Spain) were assayed. Infected groups included 18 animals naturally infected with *B. melitensis* biovar 1 or 3 (bacterial isolation in lymph nodes, spleen, etc.) and 24 rams with semen cultures positive for *Brucella ovis*. All infected animals were positive by complement fixation and gel diffusion with a hot-saline extract of *B. ovis*. Sheep infected with *B. melitensis* were also positive by the Rose Bengal test. Serum samples from 44 *Brucella*-free sheep were kindly provided by the Central Veterinary Laboratory, Weybridge, United Kingdom.

**Canine sera.** The study included two different groups of canine sera. The first group comprised individual samples from 36 dogs with confirmed ( $n = 31$ ) or suspected ( $n = 5$ ) brucellosis. This group included 24 females and 12 males, with ages ranging from 6 months to 8 years. Canine brucellosis was confirmed when *Brucella* was isolated by blood culture. Suspected brucellosis was defined by either clinical findings compatible with the disease, a history of probable contact with infected dogs, a positive result by the rapid slide agglutination test (2MER-SAT), or any combination of these.

A second group of sera included serial samples from seven dogs involved in an outbreak of canine brucellosis in a kennel. This cohort included one male and six females, whose ages ranged from 2 to 5 years. *B. canis* was isolated from blood in two cases and from vaginal discharge in one. The initial serum sample was obtained shortly after the presentation of the index case, at monthly intervals up to 5 months postinfection, and then at 9 months postinfection. Serum samples from 34 *Brucella*-free dogs were used to establish the cutoff value of each assay.

**Bovine sera.** Serum samples from 13 pregnant heifers experimentally infected with *B. abortus* 544 were analyzed. All these sera showed high titers ( $>1/80$ ) in the standard tube agglutination test and high titers ( $>4/64$ ) in the complement fixation test. Serum samples from 36 *Brucella*-free cows were included to calculate the cutoff of each ELISA. Infected and *Brucella*-free bovine sera were kindly provided by R. Kittelberger, Upper Hutt, New Zealand.

**Human sera.** Human sera were obtained from 54 patients with active brucellosis who attended the Brucellosis Section of the Hospital F. J. Muñoz (Buenos Aires, Argentina). Human brucellosis was diagnosed on the basis of clinical, serological, bacteriological (*Brucella* isolation from blood cultures), and epidemiological data. Sera from 31 healthy donors were used to calculate the cutoff of each ELISA.

**Bacterial culture and preparation of antigens.** *A. tumefaciens*, *O. anthropi*, and *S. meliloti* (kindly provided by Antonio Lagares, Universidad Nacional de La Plata, La Plata, Argentina) were grown in tryptic soy broth. Cells were killed by addition of 0.4% formaldehyde. Bacterial suspensions were centrifuged at  $16,000 \times g$  for 10 min and washed three times with 10 mM Tris-HCl, pH 8 (Tris buffer). The cells were suspended in Tris buffer (0.1 g [wet weight] of cells per ml) and disrupted with a French press (SIM-AMINCO-Espectronic Instruments). Bacterial cells were broken by two passages and then digested with DNase and RNase. Unbroken cells were separated by centrifugation. Cell envelopes were harvested by centrifugation at  $105,000 \times g$  for 4 h. The resulting supernatant (CYT) was stored at  $-20^{\circ}\text{C}$  until use. To obtain MA antigens, cell envelopes were washed twice in 10 mM Tris-HCl, pH 8.0, and resuspended in the same buffer containing 1% Triton X-100 and 5 mM EDTA. After a 4-h incubation at  $37^{\circ}\text{C}$  with constant agitation, the sample was centrifuged at  $105,000 \times g$  for 4 h. The resulting supernatant (MA) was kept at  $-20^{\circ}\text{C}$  until use. Protein concentrations in CYT and MA antigens were determined by the bicinchoninic acid method (Pierce).

**ELISA.** Maxisorp polystyrene plates (Nunc, Roskilde, Denmark) were sensitized with the corresponding CYT or MA antigen at 0.5  $\mu\text{g}$  per well diluted in phosphate-buffered saline (PBS). For some assays, antigens were incubated overnight at  $37^{\circ}\text{C}$  with 0.05  $\mu\text{g}$  of proteinase K (Promega)/ $\mu\text{l}$  before ELISA. Plates were blocked with 200  $\mu\text{l}$  of PBS containing 3% skim milk per well. After a wash with PBS containing 0.05% Tween 20 (PBS-T), sera were dispensed diluted 1:200 in PBS-T containing 1% skim milk. Specific antibodies were detected with horseradish peroxidase-conjugated antibodies against the corresponding species (human, sheep, and dog  $\gamma$  chain specific [Jackson ImmunoResearch Laboratories, Inc.]; cow  $\gamma$  chain specific [Sigma, St. Louis, Mo.]). The reaction was developed by adding *ortho*-phenylenediamine (2  $\mu\text{g}$  in 0.1 M citrate-phosphate buffer containing 0.03%  $\text{H}_2\text{O}_2$ ) and was stopped with 4 N  $\text{H}_2\text{SO}_4$ . ELISA plates were read at 490 nm in a  $\Sigma 960$  microplate reader (Metertech Inc., Taipei, Taiwan). To discount nonspecific reactivities, each sample was also tested in wells not coated with the antigen, and the specific optical density (OD) was calculated as  $\text{OD}_{\text{antigen}} - \text{OD}_{\text{no antigen}}$ . To establish the cutoff value of the assays, serum samples from noninfected controls were tested under the same conditions described above. The cutoff value of each ELISA system was calculated as the mean specific OD of control sera plus 2 standard deviations.

The same ELISA protocol was used for proteinase K-treated antigens, but a smaller number of samples of each host species was included.

**Sensitivity and specificity.** The sensitivity of each antigen for each host species was calculated from the results obtained for samples from *Brucella*-infected individuals as positives/(positives + false negatives). Specificity was calculated from the results obtained for samples from healthy controls as negatives/(negatives + false positives).

**Western blotting.** CYT and MA antigens were electrophoresed in a 12.5% polyacrylamide gel in the presence of sodium dodecyl sulfate and were electrotransferred to nitrocellulose sheets by conventional methods. After being blocked with Tris-buffered saline (TBS) containing 0.1% Tween 20, the nitrocellulose sheets were rinsed with TBS containing 0.05% Tween 20 and cut into strips. Each strip was incubated for 1 h at room temperature with serum diluted 1:200 in TBS containing 0.05% Tween 20. After a subsequent incubation with species-specific peroxidase-conjugated antibodies (see "ELISA" above), the reaction was developed with 4-chloro- $\alpha$ -naphthol (3 mg/ml) and  $\text{H}_2\text{O}_2$  (0.03%) in TBS.

**Statistical analysis.** Differences in median ODs between groups were analyzed with the Kruskal-Wallis test and Dunn's multiple comparison test by using the software included in GraphPad Prism (version 3.0; GraphPad, Inc., San Diego, Calif.).

#### RESULTS

Sera from patients and animals infected with different *Brucella* species, all of which were positive against CP and LPS from *Brucella* by ELISA (3, 17), were assayed for reactivity against CYT and MA antigens from other alpha-proteobacteria. As shown in Fig. 1, most sera from *Brucella*-infected dogs exhibited strong reactions against CYT antigens from *O. anthropi* and *S. meliloti* but weaker reactions against antigens from *A. tumefaciens*. Similar results were obtained with MA antigens (data not shown). For CYT antigens, median reactivities of sera from infected and control dogs were 1.590 and




FIG. 1. Reactivities of human and animal brucellosis sera against CYT antigens of *O. anthropi*, *S. meliloti*, and *A. tumefaciens*. I, infected hosts; N, normal (uninfected) controls. Reactivity was assessed by an indirect ELISA.

0.144 ( $P < 0.001$ ) for *O. anthropi*, 1.707 and 0.130 ( $P < 0.001$ ) for *S. meliloti*, and 0.373 and 0.167 (not significant) for *A. tumefaciens*. For MA antigens, median reactivities were 1.534 and 0.506 ( $P < 0.001$ ) for *O. anthropi*, 1.134 and 0.454 ( $P < 0.001$ ) for *S. meliloti*, and 0.805 and 1.053 (not significant) for *A. tumefaciens*. The reactivities of samples from infected dogs were directed mainly to proteinaceous antigens, as evidenced by the fact that they were greatly reduced after treatment of CYT or MA antigens with proteinase K (Fig. 2). The differential reactivity of control and brucellosis sera was also reflected in Western blotting results. As exemplified for the *O. anthropi* CYT antigens (Fig. 3), some antigens were recognized by sera from both healthy and infected dogs, but many proteins with molecular masses between 35 and 65 kDa were strongly and specifically recognized by brucellosis sera.




FIG. 2. ELISA reactivities of brucellosis (I) and control (N) sera against CYT and MA antigens from *S. meliloti* before and after treatment with proteinase K.

Cutoff values were calculated by using ODs from healthy dogs, and the sensitivity and specificity of each ELISA for canine brucellosis were determined (Table 1). All three ELISAs using CYT antigens were highly specific, and two of them (*O. anthropi* and *S. meliloti*) also showed acceptable sensitivity. Similar results were obtained when MA antigens were used (Table 1). In addition, ELISAs with CYT or MA antigens allowed diagnosis of canine brucellosis shortly after exposure to the pathogen (15 days). Initial samples from the seven recently infected dogs were positive against *O. anthropi* and *A. tumefaciens* antigens, and five were positive against *S. meliloti* antigens. The remaining two of these seven dogs became positive for *S. meliloti* antigens later during follow-up (data not shown).

In contrast with canine samples, control sera from cattle, sheep, and humans yielded high reactivities against CYT antigens, and their OD distribution was sometimes indistinguishable from that of samples from infected individuals (Fig. 1).




FIG. 3. Western blot reactivities of sera from dogs with brucellosis (lanes 1 to 6) and control dogs (lanes 7 and 8) against CYT antigens from *O. anthropi*.

TABLE 1. Diagnostic performance of ELISA using CYT and MA antigens from alpha-proteobacteria for the diagnosis of human and animal brucellosis

Antigen		Value <sup>a</sup> for the following serum samples:											
		Canine			Human			Bovine			Ovine		
Bacterium	Fraction	Cutoff	Se	Sp	Cutoff	Se	Sp	Cutoff	Se	Sp	Cutoff	Se	Sp
<i>O. anthropi</i>	CYT	0.560	84	91	1.820	0	100	1.040	6.8	97.2	0.860	63.6	95
	MA	1.080	80	94	2.280	0	100	2.300	0	100	1.230	9.52	96
<i>A. tumefaciens</i>	CYT	0.670	58	96	2.550	0	100	1.390	55	100	1.820	9	95
	MA	1.130	50	99	0.420	41	100	1.140	0	1	1.280		100
<i>S. meliloti</i>	CYT	0.400	88	96	1.500	0	100	1.010	1.7	100	1.260	4.8	95
	MA	0.280	95	100	2.220	0	100	1.570	0	97	1.100	4.8	100

<sup>a</sup> Se, sensitivity; Sp, specificity. Both sensitivity and specificity are expressed as percentages.

Similar results were obtained with MA antigens (data not shown). Since results were expressed as specific ODs ( $OD_{\text{antigen}} - OD_{\text{no antigen}}$  for each serum sample), the reactivities of control sera shown in Fig. 1 were antigen specific. Several assay modifications were tested with the aim of increasing the difference in reactivity between the two groups of samples. These included different serum dilutions (up to 1:800) and different blocking agents (0.3% gelatin, 1.0% ovalbumin, and 0.1% Tween 20, alone or combined). None of these changes resulted in an increased difference between control and pathological sera.

The high reactivities of control sera from sheep, cattle, and humans resulted in cutoff values much higher than those obtained for canine samples (Table 1). While specificities were high for all the antigens, the high cutoff values resulted in low sensitivities for the diagnosis of human, ovine, and bovine brucellosis (Table 1). In general, the lower diagnostic sensitivity for ovine and bovine brucellosis than for canine disease was not due to lower signal levels of sera from infected sheep and cattle. For *O. anthropi* CYT antigens, the median OD of sera from infected dogs did not differ significantly from that of infected sheep or cattle (1.590 versus 1.133 and 2.133, respectively). Moreover, for *A. tumefaciens* CYT antigens, the median ODs for infected sheep and cattle were significantly higher than that of canine samples (1.101 and 1.680 versus 0.373, respectively;  $P < 0.001$  for both comparisons). In contrast, reduced reactivity of sera from brucellosis patients could have contributed, in addition to the higher cutoff values, to the lower sensitivity of CYT ELISAs for human brucellosis than for canine brucellosis. Median ODs of human sera against CYT antigens from *O. anthropi* and *S. meliloti* were significantly lower than the corresponding values of canine sera (0.673 and 0.690 versus 1.590 and 1.707, respectively;  $P < 0.05$  and  $P < 0.001$ ).

To determine whether the antigens responsible for the high reactivities of uninfected ovine, bovine, and human sera were proteins, both CYT and MA antigens were treated with proteinase K before ELISA. Proteinase K digestion reduced the reactivities of sera from both healthy controls and infected individuals to CYT antigens from *S. meliloti* (Fig. 2) and from *O. anthropi* and *A. tumefaciens* (data not shown). However, bovine and ovine reactivities to CYT antigens from *A. tumefaciens* and *S. meliloti* were less affected than human reactivity to these antigens. In contrast, proteinase K reduced the reac-

tivities of sera from healthy or infected individuals of all three species against *O. anthropi* CYT antigens in a similar fashion. Overall, the results suggested that the high reactivity of control sera against *O. anthropi* CYT antigens is due mostly to proteinaceous antigens. The reactivity of human control sera to CYT antigens from *A. tumefaciens* and *S. meliloti* also seemed to be due to proteins, but those of bovine and ovine samples seemed to be directed mainly to nonproteinaceous antigens. Similar results were obtained after proteinase K treatment of MA antigens from *S. meliloti* (Fig. 2) and from *O. anthropi* and *A. tumefaciens* (data not shown).

To establish whether the antigens recognized by healthy controls were different from those recognized by sera from *Brucella*-infected humans, cattle, and sheep, Western blot analysis was performed. While for some host species and some antigens no differential reactivity was noted between sera from healthy controls and sera from *Brucella*-infected individuals, some antigens present in the CYT and MA fractions of *S. meliloti* were recognized by infected cattle but not by normal cattle (Fig. 4).




FIG. 4. Western blot reactivities of sera from cattle with brucellosis (lanes 1 to 3) and healthy cattle (lanes 4 to 6) against CYT and MA antigens from *S. meliloti*. Arrows indicate antigens recognized by infected cattle but not by healthy controls.



## DISCUSSION

Serological cross-reactivities can constitute a drawback when cross-reacting species are common pathogens, since they make the differential diagnosis of infections difficult. In contrast, if one of the species is not pathogenic and/or is unlikely to enter the host, antibodies to cross-reacting antigens should be found only in individuals infected with the pathogenic species. Therefore, cross-reacting antigens from the nonpathogenic species could be used to diagnose infections caused by the pathogenic species. While most *Brucella* species are pathogenic, many related alpha-proteobacteria are not pathogenic for immunocompetent individuals. The present study reveals the existence of extensive cross-reactivities, especially evident in infected dogs, between CYT and MA antigens from *Brucella* and those of *A. tumefaciens* and *S. meliloti*.

These serological cross-reactivities allowed the sensitive diagnosis of canine brucellosis by ELISAs performed with CYT and MA antigens from *S. meliloti* and *O. anthropi* (but less sensitive diagnosis with *A. tumefaciens*). The background reactivity of canine control sera was generally low and resulted in high specificities for all the tests.

In contrast, control sera from humans, cattle, and sheep produced rather high reactivities with most antigens, yielding high cutoff values and low diagnostic sensitivities. The reasons for the higher reactivities of these sera are unclear. One possibility is that cattle, sheep, and humans are more exposed than dogs to these alpha-proteobacteria because of their diets. Alternatively, CYT and MA components may cross-react with antigens from bacteria not belonging to the alpha-proteobacteria division that may have more frequent contact with humans or cattle than with dogs. In any case, CYT and MA antigens should be further fractionated to improve their diagnostic performance. As shown in Fig. 4, some proteins of the *S. meliloti* CYT and MA fractions were preferentially recognized by sera from infected cattle.

To our knowledge, this study is the first to assess the usefulness of antigens from nonpathogenic bacteria of related genera for the diagnosis of an infectious disease. In the few cases in which heterologous antigens have been used, they were obtained from a different species of the same genus (e.g., *Taenia crassiceps* instead of *Taenia solium* [9]) or from a different stage of the same species (e.g., *Trypanosoma epimastigotes* instead of *trypomastigotes*). The use of antigens from related nonpathogenic organisms could constitute a useful strategy to be applied when the preparation of antigens from the etiological agent is complicated by biosafety and/or bacterial growth issues. In the specific case of *Brucella*, pathogenicity is the most important issue. Expert committees, including those of the Centers for Disease Control and Prevention and the National Institutes of Health, have recommended the use of BSL-3 facilities for the large-scale culture of *Brucella* species (6). Such facilities are seldom available in the developing countries where brucellosis is more prevalent. Only *B. ovis* can be regarded as safe, since no human infections by this species have been reported. However, this species requires a controlled CO<sub>2</sub> atmosphere for growth, which can complicate production procedures. In addition, the use of antigens from nonpathogenic alpha-proteobacteria could circumvent the undesirable false-positive reactions due to smooth or rough *Brucella*

LPS (4, 7). By reducing the biosafety requirements, the use of antigens from nonpathogenic alpha-proteobacteria would simplify the production of diagnostic kits for brucellosis. While the use of recombinant antigens is also a valuable strategy for avoiding the large-scale culture of pathogenic species, the recombinant *Brucella* antigens tested to date have shown insufficient sensitivity for the diagnosis of brucellosis (5, 11). This suggests that a mixture of several proteins may be necessary to achieve high diagnostic sensitivity for brucellosis.

In summary, this study shows that CYT and MA antigens from nonpathogenic alpha-proteobacteria are recognized by sera from humans and animals infected with *Brucella*. It also shows that these antigens can be used for the specific and sensitive diagnosis of canine brucellosis. Because of the high reactivities of sera from healthy individuals, the whole CYT and MA fractions do not seem to have diagnostic usefulness for ovine, bovine, and human brucellosis. However, selected components of these fractions seemed to be preferentially recognized by infected individuals and could constitute the basis of a diagnostic assay for human and animal brucellosis.

## ACKNOWLEDGMENTS

This work was supported by grant PICT99-0506324 from the Agencia Nacional de Promoción Científica y Tecnológica (ANPCYT) and by a grant from the Fundación Antorchas. M.V.D. was supported by a fellowship of the Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET). C.A.F. and P.C.B. are members of the Research Career of CONICET. C.A.F. is also a member of the Facultad de Ciencias Exactas, Universidad Nacional de La Plata.

## REFERENCES

- Alnor, D., N. Frimodt-Moller, F. Espersen, and W. Frederiksen. 1994. Infections with the unusual human pathogens *Agrobacterium* species and *Ochrobactrum anthropi*. *Clin. Infect. Dis.* **18**:914-920.
- Amaya, R. A., and M. S. Edwards. 2003. *Agrobacterium radiobacter* bacteremia in pediatric patients: case report and review. *Pediatr. Infect. Dis. J.* **22**:183-186.
- Baldi, P. C., S. E. Miguel, C. A. Fossati, and J. C. Wallach. 1996. Serological follow-up of human brucellosis by measuring IgG antibodies directed to LPS and cytoplasmic proteins of *Brucella*. *Clin. Infect. Dis.* **22**:446-455.
- Carmichael, L. E., S. J. Zoha, and R. Flores-Castro. 1984. Problems in the serodiagnosis of canine brucellosis: dog responses to cell wall and internal antigens of *Brucella canis*. Third International Symposium on Brucellosis, Algiers. *Dev. Biol. Stand.* **56**:371-383.
- Cassataro, J., M. V. Delpino, C. A. Velikovskiy, L. Bruno, C. A. Fossati, and P. C. Baldi. 2002. Diagnostic usefulness of antibodies against the ribosome recycling factor from *Brucella melitensis* in human or canine brucellosis. *Clin. Diagn. Lab. Immunol.* **9**:366-369.
- Centers for Disease Control and Prevention and National Institutes of Health. 1999. Biosafety in microbiological and biomedical laboratories, 4th ed. U.S. Department of Health and Human Services, Washington, D.C.
- Corbel, M. J., F. A. Stuart, and R. A. Brewer. 1983. Observations of serological cross-reaction between smooth *Brucella* species and organisms of other genera. *Dev. Biol. Stand.* **56**:341-363.
- DelVecchio, V. G., V. Kapatral, R. J. Redkar, G. Patra, C. Mujer, T. Los, N. Ivanova, I. Anderson, A. Bhattacharyya, A. Lykidis, G. Reznik, L. Jablonski, N. Larsen, M. D'Souza, A. Bernal, M. Mazur, E. Goltzman, E. Selkov, P. H. Elzer, S. Hagius, D. O'Callaghan, J. J. Letesson, R. Haselkorn, N. Kyrpidis, and R. Overbeek. 2002. The genome of the facultative intracellular pathogen *Brucella melitensis*. *Proc. Natl. Acad. Sci. USA* **99**:443-448.
- Ferreira, A. P., A. J. Vaz, P. M. Nakamura, A. T. Sasaki, A. W. Ferreira, and J. A. Livramento. 1997. Hemagglutination test for the diagnosis of human neurocysticercosis: development of a stable reagent using homologous and heterologous antigens. *Rev. Inst. Med. Trop. Sao Paulo* **39**:29-33.
- Hirsch, A. M., M. R. Lum, and J. A. Downie. 2001. What makes the rhizobial-legume symbiosis so special? *Plant Physiol.* **127**:1484-1492.
- Letesson, J. J., A. Tibor, G. van Eynde, V. Wansard, V. Weynants, P. Denoel, and E. Saman. 1997. Humoral immune response of *Brucella*-infected cattle, sheep, and goats to eight purified recombinant *Brucella* proteins in an indirect enzyme-linked immunosorbent assay. *Clin. Diagn. Lab. Immunol.* **4**:556-564.
- Mahmood, M. S., A. R. Sarwari, M. A. Khan, Z. Sophie, E. Khan, and S.

- Sami. 2000. Infective endocarditis and septic embolization with *Ochrobactrum anthropi*: case report and review of literature. *J. Infect.* **40**:287–290.
13. Moreno, E., A. Cloeckert, and I. Moriyón. 2002. *Brucella* evolution and taxonomy. *Vet. Microbiol.* **90**:209–227.
  14. Paulsen, I. T., R. Seshadri, K. E. Nelson, J. A. Eisen, J. F. Heidelberg, T. D. Read, R. J. Dodson, L. Umayam, L. M. Brinkac, M. J. Beanan, S. C. Daugherty, R. T. Deboy, A. S. Durkin, J. F. Kolonay, R. Madupu, W. C. Nelson, B. Ayodeji, M. Kraul, J. Shetty, J. Malek, S. E. Van Aken, S. Riedmuller, H. Tettelin, S. R. Gill, O. White, S. L. Salzberg, D. L. Hoover, L. E. Lindler, S. M. Halling, S. M. Boyle, and C. M. Fraser. 2002. The *Brucella suis* genome reveals fundamental similarities between animal and plant pathogens and symbionts. *Proc. Natl. Acad. Sci. USA* **99**:13148–13153.
  15. Tzfira, T., and V. Citovsky. 2002. Partners-in-infection: host proteins involved in the transformation of plant cells by *Agrobacterium*. *Trends Cell. Biol.* **12**:121–129.
  16. Velasco, J., R. Diaz, M. J. Grillo, M. Barberan, C. Marin, J. M. Blasco, and I. Moriyon. 1997. Antibody and delayed-type hypersensitivity responses to *Ochrobactrum anthropi* cytosolic and outer membrane antigens in infections by smooth and rough *Brucella* spp. *Clin. Diagn. Lab. Immunol.* **4**:279–284.
  17. Wanke, M. M., M. V. Delpino, and P. C. Baldi. 2002. Comparative performance of tests using cytosolic or outer membrane antigens of *Brucella* for the serodiagnosis of canine brucellosis. *Vet. Microbiol.* **88**:367–375.